WARNING

Mirvetuximab soravtansine-gynx is an antibody-drug conjugate used in the treatment of certain types of cancer, particularly ovarian cancer. Like all medications, Mirvetuximab soravtansine-gynx carries some risks and potential side effects. Here are some of the risks associated with taking Mirvetuximab soravtansine-gynx:

• Infusion reactions: Some patients may experience allergic reactions or infusion-related reactions during or after receiving the injection. These reactions can range from mild to severe and may include symptoms like fever, chills, rash, itching, or difficulty breathing.
• Eye problems: Mirvetuximab soravtansine-gynx can cause eye problems such as blurred vision, dry eyes, or eye pain. In some cases, it may lead to more serious conditions like corneal disorders or retinal detachment.
• Liver toxicity: There is a risk of liver toxicity with Mirvetuximab soravtansine-gynx, which can manifest as elevated liver enzymes in blood tests or symptoms such as jaundice, abdominal pain, or swelling.
• Low blood cell counts: Treatment with Mirvetuximab soravtansine-gynx can lead to decreased levels of red blood cells (anemia), white blood cells (neutropenia), or platelets (thrombocytopenia), increasing the risk of infections, bleeding, and fatigue.
• Nerve damage: Some patients may experience peripheral neuropathy, which can cause numbness, tingling, weakness, or pain in the hands and feet.
• Gastrointestinal issues: Mirvetuximab soravtansine-gynx can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation.
• Increased risk of infections: Due to suppression of the immune system, patients taking Mirvetuximab soravtansine-gynx may be at a higher risk of developing infections, which can be serious.

It’s important for patients receiving Mirvetuximab soravtansine-gynx to be closely monitored by their healthcare providers for any signs of these side effects, and to report any symptoms promptly.

Why is this medication prescribed?

Mirvetuximab soravtansine-gynx Injection is prescribed for the treatment of certain types of cancer, particularly epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is used in patients whose cancer cells express a protein called FRα (folate receptor alpha), which the medication targets.

The medication works as an antibody-drug conjugate, where an antibody (mirvetuximab soravtansine) is attached to a chemotherapy drug (soravtansine). The antibody specifically targets cancer cells that express FRα, delivering the chemotherapy directly to the cancer cells while minimizing damage to healthy cells.

How should this medicine be used?

As for how they should be used:

• Dosage: The dosage of Mirvetuximab soravtansine-gynx Injection can vary depending on factors such as the patient’s weight, overall health, and the specific type and stage of cancer being treated. It is typically administered by a healthcare professional in a hospital or clinic setting.
• Administration: Mirvetuximab soravtansine-gynx Injection is given intravenously (IV), usually over a specified period of time determined by the healthcare provider. The injection is typically repeated on a scheduled basis as part of a treatment cycle.
• Precautions: Patients receiving Mirvetuximab soravtansine-gynx should be closely monitored for any signs of allergic reactions or infusion-related reactions during and after the injection. They may also need regular blood tests to monitor for side effects such as changes in blood cell counts or liver function.
• Storage: Mirvetuximab soravtansine-gynx should be stored according to the manufacturer’s instructions, typically at controlled room temperature away from light and moisture.

It’s crucial for patients to follow their healthcare provider’s instructions precisely regarding the dosage and administration of Mirvetuximab soravtansine-gynx, and to report any side effects or concerns promptly.

Other uses for this medicine

Mirvetuximab soravtansine-gynx Injection is primarily indicated for the treatment of certain types of cancer, particularly epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, in patients whose cancer cells express the folate receptor alpha (FRα). However, it is not typically used for other conditions or purposes unless specifically prescribed by a healthcare provider.

What special precautions should I follow?

Special precautions to follow when using Mirvetuximab soravtansine-gynx Injection include:

• Allergic Reactions: Inform your healthcare provider of any known allergies to medications, especially to other chemotherapy drugs or antibody-based treatments. Watch for signs of allergic reactions during and after the infusion, such as rash, itching, difficulty breathing, or swelling of the face, lips, or throat.
• Infusion Reactions: Due to the potential for infusion-related reactions, treatment with Mirvetuximab soravtansine-gynx should be administered by trained healthcare professionals in a medical facility equipped to manage such reactions. Your healthcare provider will monitor you closely during and after the infusion for any signs of adverse reactions.
• Eye Problems: Mirvetuximab soravtansine-gynx can cause eye-related adverse effects such as blurred vision, dry eyes, or eye pain. Report any changes in vision or eye discomfort to your healthcare provider promptly.
• Liver Function: Since Mirvetuximab soravtansine-gynx may cause liver toxicity, your liver function may need to be monitored regularly with blood tests during treatment. Inform your healthcare provider if you experience symptoms such as yellowing of the skin or eyes (jaundice), abdominal pain, or dark urine.
• Peripheral Neuropathy: Be aware of potential nerve damage, which can manifest as numbness, tingling, weakness, or pain in the hands and feet. Report any new or worsening symptoms to your healthcare provider.
• Infections: Due to the potential for decreased white blood cell counts (neutropenia) during treatment, you may be at increased risk of infections. Take precautions to avoid exposure to infectious agents and promptly report any signs of infection, such as fever or persistent cough.
• Pregnancy and Breastfeeding: Mirvetuximab soravtansine-gynx may cause harm to a developing fetus, so it is essential to use effective contraception during treatment and for a period after the last dose. Avoid breastfeeding while receiving treatment with Mirvetuximab soravtansine-gynx.

Always follow your healthcare provider’s instructions carefully and communicate any concerns or potential side effects promptly.

What special dietary instructions should I follow?

There are typically no specific dietary restrictions associated with Mirvetuximab soravtansine-gynx Injection. However, maintaining a balanced and nutritious diet is important for overall health and well-being during cancer treatment. Your healthcare provider or a registered dietitian may offer guidance on dietary choices that can help support your nutritional needs and manage potential side effects of treatment.

What should I do if I forget a dose?

If you forget a dose of Mirvetuximab soravtansine-gynx Injection, it is important to contact your healthcare provider or treatment facility as soon as possible for guidance. Do not attempt to administer the missed dose yourself. Your healthcare provider will advise you on the appropriate course of action, which may include rescheduling the missed dose or adjusting your treatment plan as needed. It’s essential to follow their instructions closely to ensure the effectiveness and safety of your treatment regimen.

What side effects can this medication cause?

Mirvetuximab soravtansine-gynx Injection, like many cancer treatments, can cause a range of side effects. It’s important to note that not all patients will experience these side effects, and the severity can vary from person to person. Common side effects of Mirvetuximab soravtansine-gynx Injection may include:

• Infusion reactions: These can occur during or shortly after receiving the injection and may include symptoms such as fever, chills, flushing, rash, itching, difficulty breathing, or low blood pressure.
• Eye problems: Mirvetuximab soravtansine-gynx can cause ocular side effects such as blurred vision, dry eyes, eye pain, or changes in visual acuity.
• Liver toxicity: Some patients may experience liver-related side effects, including elevated liver enzymes, hepatitis, or liver failure, which may manifest as jaundice, abdominal pain, dark urine, or fatigue.
• Hematological effects: Treatment with Mirvetuximab soravtansine-gynx can lead to decreased levels of red blood cells (anemia), white blood cells (neutropenia), or platelets (thrombocytopenia), increasing the risk of infections, bleeding, and fatigue.
• Peripheral neuropathy: This condition involves damage to the peripheral nerves and may cause symptoms such as numbness, tingling, weakness, or pain in the hands and feet.
• Gastrointestinal disturbances: Some patients may experience nausea, vomiting, diarrhea, constipation, or abdominal pain as side effects of Mirvetuximab soravtansine-gynx.
• Fatigue: Cancer treatments can often lead to fatigue, which may be exacerbated by Mirvetuximab soravtansine-gynx Injection.
• Skin reactions: Skin-related side effects such as rash, itching, or dry skin may occur in some patients.
• Infections: Due to suppression of the immune system, patients receiving Mirvetuximab soravtansine-gynx may be at increased risk of infections, which can be severe.
• Other side effects: Additional side effects may include headache, fever, joint pain, muscle pain, or respiratory symptoms.

It’s important for patients to discuss potential side effects with their healthcare provider before starting treatment and to report any symptoms promptly during treatment. Healthcare providers can offer guidance on managing side effects and may adjust treatment as needed to minimize discomfort and ensure the best possible outcome.

What should I know about storage and disposal of this medication?

Storage and Disposal: 

• Storage: Mirvetuximab soravtansine-gynx Injection should be stored according to the manufacturer’s instructions, typically at controlled room temperature. It should be kept in its original packaging and protected from light. Do not freeze the medication.
• Handling: Healthcare professionals should handle Mirvetuximab soravtansine-gynx Injection with care, following appropriate safety protocols to prevent accidental exposure. The medication should be prepared and administered in a sterile environment by trained personnel.
• Disposal: Any unused or expired Mirvetuximab soravtansine-gynx Injection should be disposed of properly according to local regulations and guidelines. It should not be flushed down the toilet or poured down the drain. Check with your healthcare provider or pharmacist for instructions on how to safely dispose of the medication.

In case of emergency/overdose

In case of emergency or overdose of Mirvetuximab soravtansine-gynx Injection, it’s essential to seek immediate medical attention. Emergency services should be contacted right away. Symptoms of overdose may include severe infusion reactions, worsening of side effects, or other adverse reactions. Healthcare professionals will provide appropriate treatment and supportive care based on the individual’s condition.

What other information should I know?

• Monitoring: Patients receiving Mirvetuximab soravtansine-gynx Injection will require regular monitoring by their healthcare provider to assess treatment response and monitor for any potential side effects or complications.
• Follow-up: It’s important to attend all scheduled appointments with your healthcare provider and follow their recommendations regarding treatment, monitoring, and supportive care.
• Contraindications: Mirvetuximab soravtansine-gynx Injection may not be suitable for individuals with certain medical conditions or allergies. Inform your healthcare provider of any pre-existing health conditions or allergies before starting treatment.
• Pregnancy and breastfeeding: Mirvetuximab soravtansine-gynx Injection may cause harm to a developing fetus and is not recommended during pregnancy. Effective contraception should be used during treatment, and breastfeeding should be avoided.
• Drug interactions: Inform your healthcare provider of all medications, supplements, or herbal products you are taking, as they may interact with Mirvetuximab soravtansine-gynx Injection and affect its effectiveness or increase the risk of side effects.

By following these guidelines and staying informed about your medication regimen, you can help ensure safe and effective treatment with Mirvetuximab soravtansine-gynx Injection.